You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Details for New Drug Application (NDA): 210220

✉ Email this page to a colleague

« Back to Dashboard

NDA 210220 describes CEFDINIR, which is a drug marketed by Alkem Labs Ltd, Anda Repository, Aurobindo Pharma, Chartwell Rx, Lupin, and Teva Pharms, and is included in twelve NDAs. It is available from twenty-seven suppliers. Additional details are available on the CEFDINIR profile page.

The generic ingredient in CEFDINIR is cefdinir. There are twelve drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the cefdinir profile page.

Summary for 210220

Tradename:	CEFDINIR
Applicant:	Alkem Labs Ltd
Ingredient:	cefdinir
Patents:	0

Pharmacology for NDA: 210220

Suppliers and Packaging for NDA: 210220

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
CEFDINIR	cefdinir	CAPSULE;ORAL	210220	ANDA	Major Pharmaceuticals	0904-7563	0904-7563-04	3 BLISTER PACK in 1 CARTON (0904-7563-04) / 10 CAPSULE in 1 BLISTER PACK
CEFDINIR	cefdinir	CAPSULE;ORAL	210220	ANDA	A-S Medication Solutions	50090-6041	50090-6041-0	10 CAPSULE in 1 BOTTLE (50090-6041-0)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	300MG
Approval Date:	Feb 19, 2021	TE:	AB	RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.